TrialNature medicine2026

Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial.

Deborah A Theodore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.